Leerink Partners Reiterates Outperform on Travere Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has reiterated its Outperform rating on Travere Therapeutics, maintaining a $20 price target. Analyst Joseph Schwartz continues to show confidence in the company's performance.
October 08, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has reiterated its Outperform rating on Travere Therapeutics, maintaining a $20 price target. This indicates continued confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $20 price target by Leerink Partners suggests positive sentiment and confidence in Travere Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price as it reflects analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100